[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glaucoma-primary-open-angle\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glaucoma-primary-open-angle":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100467708","adaptive-optics-retinal-imaging-100467708",false,"NCT05370287","Adaptive Optics Retinal Imaging","Inclusion Criteria:\n\n1. Are 21 years of age or older.\n2. Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam).\n3. Have the ability to understand and sign an informed consent.\n4. Have been diagnosed with POAG (cohort 2).\n\nExclusion Criteria:\n\n1. Are under 21 years of age.\n2. Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity).\n3. Have visual correction outside of the range +4 diopters (D) to -8 D.\n4. Have a history of adverse reaction to mydriatic drops.\n5. Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG).\n6. Do not meet the criteria for POAG as defined by the American Academy of Ophthalmology Practice Patterns (cohort 2)\n7. Have any health conditions that would contraindicate oxygen supplementation, including chronic obstructive pulmonary disease (COPD), emphysema, asthma, or any other obstructive or restrictive lung disease (RBF experiment participants only).\n8. Have a dependency on oxygen support or a baseline oxygen saturation \\\u003C95% (RBF experiment participants only).\n9. Have tested positive for COVID-19 at initial enrollment or have acute or chronic photophobia as a result of contraction.\n10. Are working under the direct supervision of Dr. Hammer.",true,"ALL","21 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"NA","The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.",[26],"Glaucoma, Primary Open Angle","RECRUITING","2026-05-06",{"date":30,"type":31},"2026-05-08","ACTUAL",{"date":33,"type":31},"2018-01-22",{"date":35,"type":20},"2028-09-30",{"name":37,"class":38},"Food and Drug Administration (FDA)","FED",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":15,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":39},"100337589","caffeine-consumption-in-glaucoma-patients-and-healthy-subjects-100337589","NCT03675412","Caffeine Consumption in Glaucoma Patients and Healthy Subjects","Acute Changes in Optic Nerve Head (ONH) and Macular Blood Flow After Caffeine Consumption in Glaucoma Patients and Healthy Subjects: A Quantitative Optic Coherence Tomography Angiography (OCTA) Study","Inclusion Criteria:\n\n* age 18 to 90 years\n* diagnosis of primary open angle glaucoma (Mild, Moderate and Advanced)\n* healthy subjects with no eye disease\n\nExclusion Criteria:\n\n* Diseases, ophthalmic or systemic, that are likely to affect OCTA results\n* greater than moderate cataract\n* nystagmus\n* inability to look at target\n* macular degeneration other than mild drusen or pigmentary changes\n* diabetic retinopathy\n* neovascular glaucoma or non-glaucoma optic neuropathies\n* current macular edema, prior laser to retina, inflammatory retinopathy or choroidopathy\n* keratoconus, corneal ectasia, central corneal scarring\n* rheumatologic diseases or Raynaud's phenomena\n* pregnant and lactating women\n* mental illness or alcohol addiction\n* pre-existing bladder symptoms, cardiac disease or sleep disorder\n* refractive spherical diopter greater than 5 or cylinder greater than 3\n* possible tolerance to caffeine (drinking more than 1 cup coffee per day).","18 Years","90 Years",{"count":50,"type":20},80,[23],"Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.",[26],[55,56,57,58,59],"Primary Open Angle Glaucoma (POAG)","Optical Coherence Tomography Angiography (OCTA)","Caffeine","Macular Blood Flow","Peripapillary Blood Flow","2025-11-12",{"date":62,"type":31},"2025-11-14",{"date":64,"type":31},"2018-12-30",{"date":66,"type":20},"2026-12-31",{"name":68,"class":69},"Wills Eye","OTHER",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":39},"100363058","phase-4-the-effect-of-lumify-on-ocular-redness-intraocular-pressure-and-eyelid-position-in-glaucoma-patients-100363058","NCT04007276","The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients","The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of primary open angle glaucoma\n* Willing and able to give informed consent\n* Current and greater than 6 weeks of brimonidine 0.2%, 0.15% or 0.1% use\n\nExclusion Criteria:\n\n* Pregnancy\n* Prisoners\n* Known allergy or sensitivities to brimonidine\n* No surgery within the past 6 months\n* No history of lid surgery or botox\n* Any other significant ophthalmologic disorder or condition with relevant effect on ocular redness, IOP, or eyelid position as evaluated by principal investigator\n* Inability to sit comfortably for 30 minutes\n* Prior use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines, or phenylephrine dilating drops within 1 week of study",{"count":78,"type":20},60,[80],"PHASE4","Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.",[83,84,85,86,87,26],"Glaucoma","Glaucoma, Open-Angle","Glaucoma; Drugs","Droopy Eyelid","Ptosis","NOT_YET_RECRUITING","2025-09-30",{"date":91,"type":31},"2025-10-01",{"date":93,"type":20},"2026-11-10",{"date":95,"type":20},"2036-06-01",{"name":97,"class":69},"Tulane University"]